Details for Patent: 8,513,202
✉ Email this page to a colleague
Which drugs does patent 8,513,202 protect, and when does it expire?
Patent 8,513,202 protects INVOKAMET XR, INVOKAMET, and INVOKANA, and is included in three NDAs.
This patent has forty-nine patent family members in thirty-eight countries.
Summary for Patent: 8,513,202
| Title: | Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate |
| Abstract: | A novel crystal form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum. |
| Inventor(s): | Nomura; Sumihiro (Osaka, JP), Kawanishi; Eiji (Osaka, JP) |
| Assignee: | Mitsubishi Tanabe Pharma Corporation (Osaka-Shi, JP) |
| Application Number: | 13/103,557 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,513,202 |
|
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 8,513,202
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | ⤷ Sign Up | ||
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | ⤷ Sign Up | ||
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-001 | Sep 20, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-001 | Sep 20, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,513,202
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2006-327019 | Dec 04, 2006 |
International Family Members for US Patent 8,513,202
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 064099 | ⤷ Sign Up | |||
| Argentina | 107510 | ⤷ Sign Up | |||
| Argentina | 118450 | ⤷ Sign Up | |||
| Australia | 2007329895 | ⤷ Sign Up | |||
| Brazil | PI0718882 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
